N-c(=x)-x-c Containing Patents (Class 514/478)
  • Patent number: 10350271
    Abstract: Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides towers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: July 16, 2019
    Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I., FYZIOLOGICKY USTAV AKADEMIE VED CR, V.V.I.
    Inventors: Lenka Maletinska, Blanka Zelezna, Jaroslav Kunes, Veronika Prazienkova
  • Patent number: 10272063
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: April 30, 2019
    Assignee: CHS Pharma, Inc.
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Patent number: 10143686
    Abstract: Disclosed herein is a new and improved therapy for the treatment of cancer, which comprises the step of altering cell membrane lipid composition by treating a cancer cell with an enzyme inhibitor which inhibits enzymes regulating the cholesterol biosynthetic pathway. One preferred protein target in the cholesterol biosynthetic pathway to inhibit is oxidosqualene cyclase. In some forms, inhibitors of one or more pathways are combined with an existing chemotherapeutic agent to combat drug resistance and enhance the therapeutic efficacy of conventional therapy.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 4, 2018
    Assignee: The Curators of the University of Missouri
    Inventors: Salman M. Hyder, Yayun Liang, Xiaoqin Zou, Sam Z. Grinter, Sheng-You Huang
  • Patent number: 10040768
    Abstract: A carbamate compound represented by formula (I), wherein, R1 represents a hydrogen atom or a C1-C3 alkyl group; R2, R3, R4 and R5 each independently represents a hydrogen atom, a halogen atom, a C1-C3 alkyl group optionally having one or more halogen atoms, a C3-C4 cycloalkyl group optionally having one or more halogen atoms or a C1-C3 alkoxy group optionally having one or more halogen atoms; Z1 represents a halogen atom; Z2 represents a halogen atom or a C1-C3 alkyl group; and m represents any one of integers from 0 to 2; has an excellent effect of controlling plant diseases.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: August 7, 2018
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Yuki Akioka
  • Patent number: 9999609
    Abstract: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: June 19, 2018
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts, Susan Marie Melnick, Duncan Taylor
  • Patent number: 9863018
    Abstract: Provided is a system for efficiently recovering trace metal from a large amount of a raw material, such as when trace metal is recovered from nickel oxide ore. This ion exchange resin has, on a carrier, an amide derivative represented by the following general formula. In the formula, R1 and R2 represent the same or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R4 represents a hydrogen atom or an arbitrary group, other than an amino group, bonded to ? carbon as an amino acid. The amide derivative is preferably a glycinamide derivative. The carrier preferably includes a primary amine and/or a secondary amine.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 9, 2018
    Assignees: Kyushu University, National University Corporation, SUMITOMO METAL MINING CO., LTD.
    Inventors: Masahiro Goto, Fukiko Kubota
  • Patent number: 9827220
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 28, 2017
    Assignee: CHS Pharma, Inc.
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Patent number: 9688620
    Abstract: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: June 27, 2017
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Sung James Lee, Susan Marie Melnick
  • Patent number: 9687550
    Abstract: The present invention is based, in part, upon the discovery of charged lipids that provide advantages when used in lipid particles for the in vivo delivery of a therapeutic agent. As such, described herein are compounds useful for delivering a nucleic acid to a cell.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: June 27, 2017
    Assignee: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Mamta Kapoor, Rajesh Kumar Kainthan
  • Patent number: 9681662
    Abstract: The invention relates to novel active substance combinations consisting of heterocyclic trifluorobutenylen of formula (1), wherein X is halogen and n is 0, 1 or 2, and of known insecticide substances. Said novel active substance combinations are suitable for fighting harmful pests like insects and nematodes.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: June 20, 2017
    Assignee: ADAMA MAKHTESHIM LTD.
    Inventors: Wolfram Andersch, Anton Kraus, Koichi Ishikawa
  • Patent number: 9492546
    Abstract: A formulation for topical administration, comprises bethanechol and a penetration enhancer. The formulation is preferably used by being maintained in the buccal cavity for a period of time prior to being swallowed.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: November 15, 2016
    Assignee: Acacia Pharma Limited
    Inventors: Ian Walker, Michael Frodsham
  • Patent number: 9464041
    Abstract: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: October 11, 2016
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts, Susan Marie Melnick, Duncan Taylor
  • Patent number: 9149454
    Abstract: Bethanechol is administered topically, for the treatment of xerostomia.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: October 6, 2015
    Assignee: Acacia Pharma Limited
    Inventors: Nicola Cooper, Julian Clive Gilbert, Robert William Gristwood, Michael Grant Wyllie
  • Patent number: 9050305
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: June 9, 2015
    Assignee: CHS Pharma, Inc.
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Publication number: 20150148415
    Abstract: The present invention considers derivatized nanomolecules with proven effectiveness to bind to actinides, more specifically uranium, during in vivo, ex vivo, in vitro or in situ assays. When assayed in vivo, the invention showed a reduction in at least kidney damage due to exposition to uranium.
    Type: Application
    Filed: November 22, 2013
    Publication date: May 28, 2015
    Inventors: Leonardo SILVA SANTOS, Rainer FISCHER, Luis GUZMAN, Fabiane M. NACHTIGALL
  • Publication number: 20150147376
    Abstract: Microparticles containing an ultraviolet light absorbing polymer and 3-iodo-2-propynyl butylcarbamate (“IPBC”) resist discoloration by sunlight and other ultraviolet light sources. Methods for preparing the microparticles produce polymer-shielded, formaldehyde-free IPBC formulations which resist discoloration and leaching, and are especially useful in water-based applications. The microparticles include a polymer or a poly(vinyl formal) homopolymer that absorbs light over a range of ultraviolet wavelengths associated with IPBC discoloration. The microparticles may be utilized in paints, stains, stuccoes, adhesives, and plastics, for example.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 28, 2015
    Inventor: Jorg Thomas Wilken
  • Publication number: 20150087700
    Abstract: The invention relates to nitrogen-containing inorganic carrier materials, more particularly to inorganic carrier materials containing organically bonded nitrogen, to their preparation and also to their use for stabilizing iodine-containing compounds, and also to binder formulations comprising them and to the use thereof for protecting industrial materials.
    Type: Application
    Filed: December 3, 2014
    Publication date: March 26, 2015
    Inventors: Andreas BOTTCHER, Hermann UHR
  • Publication number: 20150051279
    Abstract: The present invention relates to stable compositions for the fungicidal equipment of thermoplastic polymers, in particular PVC, comprising thiabendazole, at least one iodine-containing fungicide and at least one epoxide and optionally further fungicidally active compounds, and also to methods for preparing these formulations and to uses thereof for the protection of thermoplastic polymers against attack and destruction by microorganisms. Moreover, the invention relates to mold-resistant PVC materials equipped with the compositions according to the invention.
    Type: Application
    Filed: March 26, 2013
    Publication date: February 19, 2015
    Inventors: Hermann Uhr, Andreas Boettcher, Thomas Jaetsch
  • Publication number: 20150051280
    Abstract: The present invention relates to biocidal agents designed to protect industrial products against microbial, bacterial, fungal and algal infections. In particular, the present invention relates to co-crystals containing 3-iodopropynyl butylcarbamate (IPBC) and to compositions containing said co-crystals which possess improved physical, chemical and workability properties compared with the use of IPBC.
    Type: Application
    Filed: April 9, 2013
    Publication date: February 19, 2015
    Inventors: Giuseppe Resnati, Pierangelo Metrangolo, Giancarlo Terraneo, Michele Baldrighi
  • Publication number: 20150010635
    Abstract: Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound with a hydrophobic polymerizable vinyl monomer to prepare a hydrophobic solution, blending water with an emulsifier to prepare an aqueous emulsifier solution, emulsifying the hydrophobic solution in the aqueous emulsifier solution, and polymerizing the polymerizable vinyl monomer by mini-emulsion polymerization in the presence of a polymerization initiator, thereby producing a polymer containing an antibiotic compound and having an average particle size of below 1 ?m.
    Type: Application
    Filed: December 27, 2012
    Publication date: January 8, 2015
    Applicant: Japan EnviroChemicals, Ltd.
    Inventors: Junji Oshima, Hideaki Inoue
  • Patent number: 8921451
    Abstract: Use of aziridines for stabilizing iodine-containing compounds, especially biocides.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: December 30, 2014
    Assignee: LANXESS Deutschland GmbH
    Inventors: Andreas Böttcher, Bernd Koop, Peter Spetmann
  • Publication number: 20140348915
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: November 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Laura Elizabeth Bauer, Chen Mao, Ching Wah Chong, David J. Wustrow, Peter A. Virsik
  • Patent number: 8895609
    Abstract: The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: November 25, 2014
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Sung James Lee, Susan Marie Melnick
  • Patent number: 8883179
    Abstract: Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: November 11, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Wei Wang, Virginia Barnes, Harsh M. Trivedi, Tao Xu
  • Patent number: 8877806
    Abstract: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: November 4, 2014
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Abdallah Ahnaou, Wilhelmus H. I. M. Drinkenburg, Joseph Palumbo, Jonathan Sporn
  • Publication number: 20140303277
    Abstract: The invention relates to the production of nitrogen containing polymers from aziridines, to the use of these nitrogen containing polymers for stabilizing iodine containing compounds, to compositions comprising at least the nitrogen containing polymers and also iodine containing compounds, and to the use of these compositions as biocides and/or for controlling microorganisms.
    Type: Application
    Filed: November 15, 2012
    Publication date: October 9, 2014
    Inventors: Andreas Boettcher, Hermann Uhr, Peter Spetmann, Thomas Jaetsch, Joerg Fuehr
  • Publication number: 20140288142
    Abstract: The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.
    Type: Application
    Filed: June 9, 2014
    Publication date: September 25, 2014
    Inventors: Nicoletta ALMIRANTE, Stefano BIONDI, Ennio ONGINI, Laura STORONI, Alessia NICOTRA
  • Publication number: 20140223609
    Abstract: Embodiments of the present invention relate to insecticidal Bacillus thuringiensis Cry1 and Cry2 polypeptides. Methods for using the polypeptides and nucleic acids of embodiments of the invention to synergistically enhance resistance of plants to insect predation are encompassed in embodiments of the present invention.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 7, 2014
    Applicants: E I DU PONT DE NEMOURS AND COMPANY, PIONEER HI BRED INTERNATIONAL INC
    Inventors: John Lindsey Flexner, Deirdre Kapka-Kitzman, Lisa Procyk, Bruce H. Stanley, Jianzhou Zhao
  • Publication number: 20140213645
    Abstract: A biocide, e.g. IPBC (3-iodo-2-propynl butylcarbamate), is stabilized against thermal degradation in matrix compositions which are processed at elevated temperatures, by blending the IPBC with a stabilizer additive, e.g. calcium stearate and/or a hindered phenol, alone or in combination therewith.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Inventor: Joseph A. Bartko
  • Patent number: 8785443
    Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: July 22, 2014
    Assignee: XenoPort, Inc.
    Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
  • Publication number: 20140187629
    Abstract: A formulation for topical administration, comprises bethanechol and a penetration enhancer. The formulation is preferably used by being maintained in the buccal cavity for a period of time prior to being swallowed.
    Type: Application
    Filed: May 4, 2012
    Publication date: July 3, 2014
    Inventors: Ian Walker, Michael Frodsham
  • Publication number: 20140187628
    Abstract: The invention relates to a liquid vehicle that can be used to create suspensions and/or solutions of liquid or powdered medications. The vehicle is thixotropic and has improved stability and rheologic characteristics. Vehicles of the invention include an aqueous medium and a suspending agent comprising a polysaccharide having at least 50% glucose repeating saccharide units and at least 90% alpha linkages. The polysaccharide can be a starch, modified starch, or glycogen. The aqueous medium and individual components of the vehicle provide a palatable and easily ingested drug preparation. The invention also provides a vehicle containing an aqueous medium, suspending agent comprising a polysaccharide having at least 50% glucose repeating saccharide units and at least 90% alpha linkages, buffer, and artificial sweetener, the combined suspending vehicle having a pH of about 3 to about 10 and an osmolality of 300 mOmsol or less.
    Type: Application
    Filed: September 23, 2013
    Publication date: July 3, 2014
    Applicant: Fagron, Inc
    Inventors: Joshua Radke, Michael Jones, Martin Erickson
  • Patent number: 8741950
    Abstract: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: June 3, 2014
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts, Susan Marie Melnick, Duncan Taylor
  • Publication number: 20140100271
    Abstract: There is provided a compound of Formula (I) and salts thereof, where R1 is an oxime or an alkylated oxime; the alkylated oxime comprises a linear or branched alkyl group of length C1 to C5; and R2 are each independently (a) an unsubstituted or substituted linear or branched alkyl group of chain length C1-7, (b) an aryl substituted alkyl group, where the aryl group is substituted, (c) an alkoxy substituted alkyl group, where the alkoxy group is substituted by a methoxy group or an alkoxy group substituted with an alkoxy group, or (d) an H atom, where the substituents in (a) and (b) are hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, nitro, oxo or fluoro groups. The compounds may be used as a medicament.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 10, 2014
    Applicant: Swedish Pharma AB c/o Inkubera AB
    Inventors: Leif A. ERIKSSON, Lennart LÖFGREN
  • Patent number: 8664247
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 4, 2014
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Publication number: 20140056978
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Laura Elizabeth Bauer, Chen Mao, Ching Wah Chong, David J. Wustrow, Peter A. Virsik
  • Patent number: 8653131
    Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: February 18, 2014
    Assignees: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Guohan Yang, Ton That Hai, Bennett P. Melnick, Paul Sanders, Cong Jiang, Catherine Quinn, Jie Li, Arounaguiry Ambroise, Larry R. Brown
  • Publication number: 20140039016
    Abstract: A method of protecting wood through enhanced penetration of wood preservatives includes providing a solution including (a) at least one amine oxide, (b) at least one organic wood preservative and (c) a non-borate buffering based agent. The solution has a pH of 5 to 12.4 and preferably about 7 to 10. The solution is applied to the surface of the wood after which, with or without intervening storage, the materials are activated to effect enhanced penetration of the organic wood preservative into the wood. One may effect application at a solution temperature of about 30° C. to 75° C. and preferably about 50° C. to 60° C. to effect activation at a higher temperature and high relative humidity. In a preferred practice, the wood may be heated before and/or after application of the solution. The solution is also disclosed as a product.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 6, 2014
    Inventors: ALAN S. ROSS, KENNETH ALLEN CUTLER
  • Patent number: 8618162
    Abstract: The present invention includes insecticidal carbamates that are useful, for example, for the control of insects, such as mosquitoes, which can be used in applications where exposure to and/or contact with humans is likely. The insecticides of the present invention include phenyl N-methyl carbamates and compositions comprising them that exhibit species-selective inhibition of acetylcholinesterase (AChE) and are preferably toxic to mosquitoes but not humans. Of particular interest are compounds of Formula (I) and Formula (II): Compounds of Formula (I) and Formula (II) are especially suitable for insecticide treated nets and indoor residual spraying for mosquito control.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: December 31, 2013
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Paul Carlier, Jeffrey Bloomquist, Sally Paulson, Eric Wong
  • Patent number: 8604015
    Abstract: Compounds according to formula (I) are effective for the treatment of broncho-obstructive and inflammatory diseases.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: December 10, 2013
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele Amari, Mauro Riccaboni, Daniele De Zani
  • Publication number: 20130324539
    Abstract: Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 5, 2013
    Inventors: Peter A. Virsik, David J. Wustrow, Thamil Annamalai
  • Patent number: 8597876
    Abstract: Disclosed is a method of treating human immunodeficiency virus (HIV) infection in an antiretroviral treatment-experienced mammal, which involves administering to the mammal an effective amount of a compound of the formula: or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of the compound, the salt, the prodrug, or the ester thereof, wherein A, X, Q, W, m, and R2-R6 are as defined herein.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: December 3, 2013
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Board of Trustees of the University of Illinois
    Inventors: John W. Erickson, Sergei V. Gulnik, Hiroaki Mitsuya, Arun K. Ghosh
  • Publication number: 20130259824
    Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
    Type: Application
    Filed: March 29, 2013
    Publication date: October 3, 2013
    Inventors: Jang-Yen Wu, Howard Malcolm Prentice
  • Publication number: 20130261133
    Abstract: The compounds of the invention exhibit antiprotozoal, antimicrobial, and anticancer properties that are useful for the treatment or prevention of infections or cancer in a patient (e.g., a human). For example, the compounds and methods described herein can be used for the treatment or prevention of protozoal infections such as leishmaniasis, malaria, and trypanosoma infections, bacterial infections such as S. aureus and C. albicans, and cancers such as breast, colon, lung, or prostate cancer. The invention further provides methods of synthesizing such compounds as well as kits useful for administering the compounds.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 3, 2013
    Applicant: The University of Montana
    Inventors: John Howard Hoody, David Brian Bolstad
  • Publication number: 20130195947
    Abstract: A storage stable, free flowing powder concentrate for use in the manufacture of a biocide formulation comprises a t biocide containing an iodopropynyl group and an inert filler, wherein the wt % ratio of biocide: inert filler is from about 1:1 to about 1:100 and the wt % of biocide is not more than 50%.
    Type: Application
    Filed: March 17, 2011
    Publication date: August 1, 2013
    Inventor: Willem Anker
  • Publication number: 20130172385
    Abstract: The present invention relates to compositions comprising certain active compounds which are suitable as repellents, and to their use for preventing an infection of humans or of animals by the infectious states of parasitic flatworms (platyhelminths).
    Type: Application
    Filed: May 9, 2008
    Publication date: July 4, 2013
    Applicant: LANXESS DEUTSCHLAND GMBH
    Inventors: Achim Harder, Georg von Samson-Himmlstjerna, Bernd-Wieland Kruger, Heinz Mehlhorn, Jurgen Schmidt
  • Publication number: 20130165508
    Abstract: Disclosed embodiments describe pharmaceutical compositions and methods for treating ineffective esophageal motility in which bethanechol and pharmaceutically acceptable absorption enhancers including bile acids and mixtures thereof are topically introduced to the esophagus. Therapeutically effective amounts of bethanechol are delivered while reducing or eliminating parasympathetic nervous system side effects normally associated with systemic bethanechol delivery.
    Type: Application
    Filed: February 20, 2013
    Publication date: June 27, 2013
    Inventor: Robert C. Stover
  • Patent number: 8450506
    Abstract: The present invention relates to compounds of formula (I), where R1 and R2, which may be identical or different, are selected from the group comprising H, CnH2n-1, a linear or branched alkyl group having 1 to 6 carbons, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R3 is —CO—CH3, —NHOH, —OH, or —OR6 where R6 is a linear or branched alkyl group having 1 to 6 carbon atoms; R4 is H, linear or branched alkyl group having from 1 to 6 atoms, phenyl, benzyl, —CF3 or CF2CF3, vinyl or allyl; R5, R7, R8 are hydrogen atoms; or R3 and R4, R4 and R5, or R7 and R8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: May 28, 2013
    Assignee: Nogra Pharma Limited
    Inventors: Giancarlo Naccari, Sergio Baroni
  • Patent number: 8440854
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: May 14, 2013
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Xin Jiang, Melean Visnick
  • Patent number: 8440715
    Abstract: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: May 14, 2013
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Abdallah Ahnaou, Wilhelmus H. L. M. Drinkenburg, Joseph Palumbo, Jonathan Sporn